0EH Stock Overview
A biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Toleranzia AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.037 |
| 52 Week High | SEK 0.048 |
| 52 Week Low | SEK 0.011 |
| Beta | 1.43 |
| 11 Month Change | -1.58% |
| 3 Month Change | 30.77% |
| 1 Year Change | -18.70% |
| 33 Year Change | -68.31% |
| 5 Year Change | n/a |
| Change since IPO | -72.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0EH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.1% | 1.2% | 0.8% |
| 1Y | -18.7% | -16.0% | 6.1% |
Return vs Industry: 0EH underperformed the German Biotechs industry which returned -16% over the past year.
Return vs Market: 0EH underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| 0EH volatility | |
|---|---|
| 0EH Average Weekly Movement | 23.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 0EH's share price has been volatile over the past 3 months.
Volatility Over Time: 0EH's weekly volatility has decreased from 29% to 23% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 10 | Charlotte Fribert | www.toleranzia.se |
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease.
Toleranzia AB Fundamentals Summary
| 0EH fundamental statistics | |
|---|---|
| Market cap | €10.82m |
| Earnings (TTM) | -€554.13k |
| Revenue (TTM) | €4.02m |
2.7x
P/S Ratio-19.5x
P/E RatioIs 0EH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0EH income statement (TTM) | |
|---|---|
| Revenue | SEK 45.66m |
| Cost of Revenue | SEK 46.03m |
| Gross Profit | -SEK 375.00k |
| Other Expenses | SEK 5.92m |
| Earnings | -SEK 6.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -0.032 |
| Gross Margin | -0.82% |
| Net Profit Margin | -13.79% |
| Debt/Equity Ratio | 0% |
How did 0EH perform over the long term?
See historical performance and comparison